FAQ FILE
Common questions about retatrutide, answered from the published record.
Mechanism, status, results, side effects, availability — direct answers, cited where quantitative.
Does retatrutide reduce liver fat in MASLD patients?
Yes — in a 48-week Phase 2a substudy in 98 participants with obesity and MASLD (fatty liver disease linked to metabolic risk factors), retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks on MRI-PDFF. Eighty-six percent of participants in that group reached normal liver-fat levels (<5%). By 48 weeks, the reduction was -86.0% at 12 mg [5]. This is the largest published liver-fat reduction in a Phase 2 trial for any pharmacological agent.
What does retatrutide do?
Retatrutide simultaneously activates three hormone receptors: GLP-1 (appetite suppression, insulin release, slowed gastric emptying), GIP (insulin augmentation, adipose metabolism), and glucagon (increased energy expenditure, hepatic lipid clearance). The combined triple-receptor mechanism drives larger weight loss and liver-fat reduction in trials than prior single- or dual-receptor approaches. A 2025 review characterized retatrutide's up-to-24% weight loss at 48 weeks as a step-change versus prior incretin therapies [6].
How does retatrutide work?
Retatrutide is a single synthetic peptide engineered to bind and activate GLP-1R, GIPR, and GCGR simultaneously. Cryo-EM structures confirmed triple engagement [3]. GLP-1R suppresses appetite and slows gastric emptying. GIPR augments insulin secretion. GCGR increases energy expenditure and hepatic lipid metabolism via cAMP/PKA signaling. In the 48-week Phase 2 obesity trial, 12 mg once weekly produced -24.2% body-weight change versus -2.1% placebo [1]. For the full mechanistic read, see how does retatrutide work.
How to reconstitute retatrutide?
Retatrutide does not have an approved reconstitution protocol. In clinical trials, it was administered as a pre-filled pen injector, not as a lyophilized powder requiring reconstitution. There is no FDA-approved or manufacturer-issued standard for preparing research-labeled retatrutide vials. Any reconstitution guide circulating online is derived from community practice, not verified pharmaceutical protocol.
Is retatrutide FDA approved?
No. Retatrutide is not approved by the FDA or any regulatory agency as of mid-2026. It is an investigational new drug in Phase 3 clinical trials under Eli Lilly's TRIUMPH program — studying obesity, type 2 diabetes, and cardiovascular and kidney outcomes. No new drug application has been filed or accepted. This is the key distinction from semaglutide and tirzepatide, which are approved drugs. Retatrutide is not.
When will retatrutide be available?
No approved availability date exists. Phase 3 TRIUMPH trials are ongoing. If results support a regulatory submission and the FDA accepts a new drug application, standard review takes 10-12 months. No submission has been publicly announced. Speculative timelines in community forums are not based on confirmed Eli Lilly filing schedules.
How to take retatrutide?
This site documents clinical trial protocols, not personal use instructions. In Phase 2 trials, retatrutide was administered as a once-weekly subcutaneous injection using a pre-filled pen, with dose escalation — starting at a lower dose and stepping up over weeks to manage GI tolerability. This was done under physician monitoring in a clinical setting, not self-administered from unregulated supply. Retatrutide is not available as a prescription outside clinical trials.
How long does retatrutide take to work?
Trial data show measurable weight changes within the first 4-12 weeks, with reductions continuing through the full 48-week Phase 2 period. In the Phase 1b study, the highest-dose group lost 8.96 kg placebo-adjusted over 12 weeks [4]. In the MASLD substudy, significant liver-fat reductions were documented at 24 weeks, with continued reduction through 48 weeks [5]. The 6-day half-life means steady-state plasma levels are reached at approximately 3-4 weeks of once-weekly dosing.
Is retatrutide better than tirzepatide?
No head-to-head trial has reported results. The comparison in the literature is cross-trial: retatrutide's Phase 2 weight-loss figure (-24.2%) exceeds tirzepatide's comparable Phase 2 figure, and a systematic review found retatrutide's liver-fat reduction (81% placebo-subtracted MRI-PDFF) the largest among agents reviewed — versus tirzepatide at 47% and semaglutide at 41% [7]. Eli Lilly has registered a Phase 3 TRIUMPH trial with a tirzepatide active-comparator arm, but results are not yet published.
How much retatrutide per week?
In Phase 2 trials, doses of 1, 4, 8, and 12 mg once weekly were studied in obesity; 0.5 to 12 mg once weekly with stepwise escalation were studied in type 2 diabetes [1][2]. These are study-design facts — the doses administered to trial participants under physician monitoring. Retatrutide is not commercially available, has no approved dosing, and is not prescribed by pharmacists or physicians outside trials.
How to mix retatrutide with bacteriostatic water?
Retatrutide was not administered as a lyophilized powder in published clinical trials — it was supplied as a pre-filled pen injector. There is no verified mixing protocol for research-labeled retatrutide vials. Protocols circulating in community forums are derived from practices applied to other research peptides and have no verified applicability to retatrutide's specific formulation requirements. This site does not provide mixing instructions.
How to switch from tirzepatide to retatrutide?
No published clinical protocol exists for switching between these agents. Tirzepatide is approved; retatrutide is not. There is no physician-guided switch protocol because retatrutide is not available outside clinical trials. Cross-trial comparison data (from descriptive systematic reviews) show both agents act on overlapping receptor populations — a pharmacology consideration for any future trial design — but this is not a clinical switching guide.
Is retatrutide a GLP-3?
No. "GLP-3" is a misnomer and a common misconception. There is no GLP-3 receptor. Retatrutide is a triple agonist at three existing receptors: GLP-1 (glucagon-like peptide-1 receptor), GIP (glucose-dependent insulinotropic polypeptide receptor), and glucagon receptor. The "GLP-3" label appears in community discussion but is not a pharmacological category. Retatrutide is correctly described as a GIP/GLP-1/glucagon triagonist or triple incretin/glucagon agonist [3].
Is retatrutide available?
Retatrutide is not commercially available as a prescription drug or approved product. The only legitimate access is enrollment in an active clinical trial. A gray market for research-labeled material exists; the FDA issued more than 50 warning letters to vendors in 2025 for FD&C Act violations. Research-labeled material is unregulated — purity, identity, and sterility are unverified, and there is no clinical oversight of its use outside trials.
What is retatrutide used for?
Retatrutide is being studied in clinical trials for obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and for cardiovascular and kidney outcomes. It has no approved indication. In Phase 2 trials, it reduced body weight by up to 24.2%, lowered HbA1c by up to 2.02%, and reduced liver fat by up to 82.4% [1][2][5]. A 2025 review characterized its triple-agonist mechanism as a step-change in the incretin pharmacology class [6].
What receptors does retatrutide target?
Retatrutide simultaneously targets three G-protein-coupled receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). Cryo-EM structural studies confirmed simultaneous triple engagement, with relative potency of 8.9 times native GIP at the GIPR, 0.3 times native glucagon at the GCGR, and 0.4 times native GLP-1 at the GLP-1R [3]. This engineered selectivity is the pharmacological basis for the efficacy and safety profile seen in trials.
Is retatrutide legal?
Retatrutide is an investigational new drug. It is legal to study in authorized clinical trials. It is legal for Eli Lilly to manufacture and distribute for trial purposes under IND authorization. It is not legal to market or sell as a drug without FDA approval, which it does not have. The FDA's issuance of more than 50 warning letters to vendors in 2025 reflects enforcement actions against gray-market retatrutide sales. Research-labeled compounds occupy a complex regulatory zone — not explicitly scheduled as controlled substances, but not lawfully marketed as drugs.
How often do you take retatrutide?
In all Phase 2 trials, retatrutide was administered once weekly via subcutaneous injection. The approximately 6-day half-life established in Phase 1b supports once-weekly dosing — it maintains pharmacologically relevant plasma levels across the 7-day interval [4]. This was the dosing schedule across all studied dose levels from 1 to 12 mg.
What is the half-life of retatrutide?
Approximately 6 days, established in the Phase 1b first-in-human study in 72 adults with type 2 diabetes [4]. The extended half-life derives from C20 fatty-diacid acylation that enables albumin binding — slowing plasma clearance. A 6-day half-life supports once-weekly dosing; steady-state plasma levels are reached at approximately 3-4 weeks of once-weekly administration.
How to store retatrutide?
Retatrutide has no approved pharmaceutical labeling — including no approved storage guidance for any product outside a clinical trial. In the published trials, the investigational product was supplied and stored per clinical-site protocols not publicly detailed. Research-labeled vials circulating outside trials do not come with verified storage guidance derived from validated pharmaceutical stability data for retatrutide specifically.
Is retatrutide the same as Ozempic?
No. Retatrutide and semaglutide (the generic name for the compound in branded semaglutide products) are distinct molecules with different mechanisms, approval statuses, and trial profiles. Semaglutide is a GLP-1 receptor agonist — it targets one receptor. Retatrutide is a triple agonist targeting GLP-1R, GIPR, and GCGR simultaneously. Semaglutide is FDA-approved for type 2 diabetes and chronic weight management. Retatrutide is not approved. They are not the same compound, not the same drug class, and not interchangeable.
Is retatrutide better than semaglutide?
No head-to-head trial of retatrutide versus semaglutide has been published. Cross-trial, descriptive comparisons show retatrutide's Phase 2 weight-loss figure (-24.2% at 48 weeks) exceeds semaglutide's largest Phase 3 figure (-14.9% at 68 weeks in the STEP-1 trial for chronic weight management, 2.4 mg). For liver fat, a systematic review found retatrutide reduced MRI-PDFF by 81% placebo-subtracted versus 41% for semaglutide [7]. These comparisons are not powered head-to-head results — they are descriptive cross-trial figures. Semaglutide is an approved drug with a long post-market safety record; retatrutide is investigational with Phase 2 safety data only.